CNR2 and multiple sclerosis: In animal models of multiple sclerosis, CB2 receptor activation by CB2 agonists has been shown to ameliorate the disease progression by reducing the demyelination of the nerves, hypersensitivity and associated neuropathic pain (Fu and Taylor, 2015).